{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:28Z","timestamp":1772166508450,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K17314"],"award-info":[{"award-number":["JP20K17314"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K08426"],"award-info":[{"award-number":["JP22K08426"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Foundation for Applied Enzymology,Japan"},{"DOI":"10.13039\/100020050","name":"Japan Intractable Diseases Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis in the skin and internal organs, such as the lungs. Activated differentiation of progenitor cells, which are mainly resident fibroblasts, into myofibroblasts is considered a key mechanism underlying the overproduction of extracellular matrix and the resultant tissue fibrosis in SSc. Calpains are members of the Ca\n                      <jats:sup>2+<\/jats:sup>\n                      -dependent cysteine protease family, whose enzymatic activities participate in signal transduction and tissue remodeling, potentially contributing to fibrosis in various organs. However, the roles of calpain in the pathogenesis of SSc remain unknown. This study aimed to examine the anti-fibrotic properties of N-acetyl-Leu-Leu-norleucinal (ALLN), one of the cysteine proteinase inhibitors that primarily inhibit calpain, in vitro and in vivo, to optimally translate into the therapeutic utility in human SSc.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Normal human dermal and lung fibroblasts pretreated with ALLN were stimulated with recombinant transforming growth factor beta 1 (TGF-\u03b21), followed by assessment of TGF-\u03b21\/Smad signaling and fibrogenic molecules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ALLN treatment significantly inhibited TGF-\u03b21-induced phosphorylation and nuclear transport of Smad2\/3 in skin and lung fibroblasts. TGF-\u03b21-dependent increases in \u03b1-smooth muscle actin (\u03b1SMA), collagen type I, fibronectin 1, and some mesenchymal transcription markers were attenuated by ALLN. Moreover, our findings suggest that ALLN inhibits TGF-\u03b21-induced mesenchymal transition in human lung epithelial cells. Consistent with these in vitro findings, administering ALLN (3\u00a0mg\/kg\/day) three times a week intraperitoneally remarkably suppressed the development of skin and lung fibrosis in a SSc mouse model induced by daily subcutaneous bleomycin injection. The number of skin- and lung-infiltrating CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells decreased in ALLN-treated mice compared with that in control-treated mice. Phosphorylation of Smad3 and\/or an increase in \u03b1SMA-positive myofibroblasts was significantly inhibited by ALLN treatment on the skin and lungs. However, no adverse effects were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results prove that calpains can be a novel therapeutic target for skin and lung fibrosis in SSc, considering its inhibitor ALLN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-023-03130-7","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T02:02:14Z","timestamp":1692928934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A cysteine proteinase inhibitor ALLN alleviates bleomycin-induced skin and lung fibrosis"],"prefix":"10.1186","volume":"25","author":[{"given":"Hiroshi","family":"Kasamatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenao","family":"Chino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritaka","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-2682","authenticated-orcid":false,"given":"Minoru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"issue":"12","key":"3130_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler JHW, Gy\u00f6rfi AH, Ramanujam M, Whitfield ML, K\u00f6nigshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol. 2019;15(12):705\u201330.","journal-title":"Nat Rev Rheumatol"},{"key":"3130_CR2","doi-asserted-by":"crossref","unstructured":"Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, Khanna D. Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies. Clin Rev Allergy Immunol. 2023;64(3):239\u201361.","DOI":"10.1007\/s12016-021-08891-0"},{"issue":"26","key":"3130_CR3","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"3130_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963\u201374.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"3130_CR5","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489\u201397.","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"3130_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1152\/physrev.00029.2002","volume":"83","author":"DE Goll","year":"2003","unstructured":"Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83(3):731\u2013801.","journal-title":"Physiol Rev"},{"issue":"12","key":"3130_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nrd.2016.212","volume":"15","author":"Y Ono","year":"2016","unstructured":"Ono Y, Saido TC, Sorimachi H. Calpain research for drug discovery: challenges and potential. Nat Rev Drug Discov. 2016;15(12):854\u201376.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3130_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nrc3050","volume":"11","author":"SJ Storr","year":"2011","unstructured":"Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011;11(5):364\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3130_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/14728222.2022.2047178","volume":"26","author":"I Shapovalov","year":"2022","unstructured":"Shapovalov I, Harper D, Greer PA. Calpain as a therapeutic target in cancer. Expert Opin Ther Targets. 2022;26(3):217\u201331.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"3130_CR10","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1128\/MCB.21.6.2213-2220.2001","volume":"21","author":"M Azam","year":"2001","unstructured":"Azam M, Andrabi SS, Sahr KE, Kamath L, Kuliopulos A, Chishti AH. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol. 2001;21(6):2213\u201320.","journal-title":"Mol Cell Biol"},{"key":"3130_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-213X-6-3","volume":"6","author":"P Dutt","year":"2006","unstructured":"Dutt P, Croall DE, Arthur JS, Veyra TD, Williams K, Elce JS, et al. m-Calpain is required for preimplantation embryonic development in mice. BMC Dev Biol. 2006;6:3.","journal-title":"BMC Dev Biol"},{"issue":"19","key":"3130_CR12","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1128\/MCB.05189-11","volume":"31","author":"J Takano","year":"2011","unstructured":"Takano J, Mihira N, Fujioka R, Hosoki E, Chishti AH, Saido TC. Vital role of the calpain-calpastatin system for placental-integrity-dependent embryonic survival. Mol Cell Biol. 2011;31(19):4097\u2013106.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"3130_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1365-2249.2010.04257.x","volume":"162","author":"C Tabata","year":"2010","unstructured":"Tabata C, Tabata R, Nakano T. The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice. Clin Exp Immunol. 2010;162(3):560\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"3130_CR14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.bbadis.2015.06.008","volume":"1852","author":"FZ Li","year":"2015","unstructured":"Li FZ, Cai PC, Song LJ, Zhou LL, Zhang Q, Rao SS, et al. Crosstalk between calpain activation and TGF-\u03b21 augments collagen-I synthesis in pulmonary fibrosis. Biochim Biophys Acta. 2015;1852(9):1796\u2013804.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"3130_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1046\/j.1523-1747.1999.00528.x","volume":"112","author":"T Yamamoto","year":"1999","unstructured":"Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999;112(4):456\u201362.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3130_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/art.27428","volume":"62","author":"C Tanaka","year":"2010","unstructured":"Tanaka C, Fujimoto M, Hamaguchi Y, Sato S, Takehara K, Hasegawa M. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator\/inducible costimulator ligand pathway. Arthritis Rheum. 2010;62(6):1723\u201332.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3130_CR17","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.4049\/jimmunol.1401779","volume":"194","author":"C Li","year":"2015","unstructured":"Li C, Iness A, Yoon J, Grider JR, Murthy KS, Kellum JM, et al. Noncanonical STAT3 activation regulates excess TGF-\u03b21 and collagen I expression in muscle of stricturing Crohn\u2019s disease. J Immunol. 2015;194(7):3422\u201331.","journal-title":"J Immunol"},{"issue":"11","key":"3130_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/jca.15566","volume":"7","author":"KJ Chen","year":"2016","unstructured":"Chen KJ, Li Q, Wen CM, Duan ZX, Zhang JY, Xu C, et al. Bleomycin (BLM) induces epithelial-to-mesenchymal transition in cultured A549 cells via the TGF-\u03b2\/Smad signaling pathway. J Cancer. 2016;7(11):1557\u201364.","journal-title":"J Cancer"},{"key":"3130_CR19","doi-asserted-by":"publisher","first-page":"595811","DOI":"10.3389\/fimmu.2021.595811","volume":"12","author":"E Valenzi","year":"2021","unstructured":"Valenzi E, Tabib T, Papazoglou A, Sembrat J, Trejo Bittar HE, Rojas M, et al. Disparate interferon signaling and shared aberrant basaloid cells in single-cell profiling of idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. Front Immunol. 2021;12:595811.","journal-title":"Front Immunol"},{"issue":"5","key":"3130_CR20","doi-asserted-by":"publisher","first-page":"e37084","DOI":"10.1371\/journal.pone.0037084","volume":"7","author":"D Nassar","year":"2012","unstructured":"Nassar D, Letavernier E, Baud L, Aractingi S, Khosrotehrani K. Calpain activity is essential in skin wound healing and contributes to scar formation. PLoS One. 2012;7(5):e37084.","journal-title":"PLoS One"},{"issue":"2","key":"3130_CR21","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1096\/fj.201800588RR","volume":"33","author":"T Miyazaki","year":"2019","unstructured":"Miyazaki T, Haraguchi S, Kim-Kaneyama JR, Miyazaki A. Endothelial calpain systems orchestrate myofibroblast differentiation during wound healing. FASEB J. 2019;33(2):2037\u201346.","journal-title":"FASEB J"},{"issue":"7","key":"3130_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-020-02737-x","volume":"11","author":"C Yi","year":"2020","unstructured":"Yi C, Wu W, Zheng D, Peng G, Huang H, Shen Z, et al. Targeted inhibition of endothelial calpain delays wound healing by reducing inflammation and angiogenesis. Cell Death Dis. 2020;11(7):533.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3130_CR23","doi-asserted-by":"publisher","first-page":"e20190103","DOI":"10.1084\/jem.20190103","volume":"217","author":"N Frangogiannis","year":"2020","unstructured":"Frangogiannis N. Transforming growth factor-\u03b2 in tissue fibrosis. J Exp Med. 2020;217(3):e20190103.","journal-title":"J Exp Med"},{"issue":"1","key":"3130_CR24","doi-asserted-by":"publisher","first-page":"111886","DOI":"10.1016\/j.yexcr.2020.111886","volume":"391","author":"M Zou","year":"2020","unstructured":"Zou M, Zhang G, Zou J, Liu Y, Liu B, Hu X, et al. Inhibition of the ERK1\/2-ubiquitous calpains pathway attenuates experimental pulmonary fibrosis in vivo and in vitro. Exp Cell Res. 2020;391(1):111886.","journal-title":"Exp Cell Res"},{"issue":"1 Suppl","key":"3130_CR25","first-page":"e487","volume":"128","author":"H Noma","year":"2009","unstructured":"Noma H, Kato T, Fujita H, Kitagawa M, Yamano T, Kitagawa S. Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes. Immunology. 2009;128(1 Suppl):e487\u201396.","journal-title":"Immunology"},{"issue":"3","key":"3130_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/jnr.21882","volume":"87","author":"JT Butler","year":"2009","unstructured":"Butler JT, Samantaray S, Beeson CC, Ray SK, Banik NL. Involvement of calpain in the process of Jurkat T cell chemotaxis. J Neurosci Res. 2009;87(3):626\u201335.","journal-title":"J Neurosci Res"},{"issue":"2","key":"3130_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/jhep.2003.50069","volume":"37","author":"GA Upadhya","year":"2003","unstructured":"Upadhya GA, Topp SA, Hotchkiss RS, Anagli J, Strasberg SM. Effect of cold preservation on intracellular calcium concentration and calpain activity in rat sinusoidal endothelial cells. Hepatology. 2003;37(2):313\u201323.","journal-title":"Hepatology"},{"issue":"1","key":"3130_CR28","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1038\/s41467-021-24607-6","volume":"12","author":"T Tabib","year":"2021","unstructured":"Tabib T, Huang M, Morse N, Papazoglou A, Behera R, Jia M, et al. Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin. Nat Commun. 2021;12(1):4384.","journal-title":"Nat Commun"},{"issue":"3","key":"3130_CR29","first-page":"1402","volume":"9","author":"WJ Tan","year":"2017","unstructured":"Tan WJ, Tan QY, Wang T, Lian M, Zhang L, Cheng ZS. Calpain 1 regulates TGF-\u03b21-induced epithelial-mesenchymal transition in human lung epithelial cells via PI3K\/Akt signaling pathway. Am J Transl Res. 2017;9(3):1402\u20139.","journal-title":"Am J Transl Res"},{"issue":"4","key":"3130_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/exd.12920","volume":"25","author":"T Yamashita","year":"2016","unstructured":"Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Takahashi T, et al. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis. Exp Dermatol. 2016;25(4):287\u201392.","journal-title":"Exp Dermatol"},{"issue":"2","key":"3130_CR31","doi-asserted-by":"publisher","first-page":"e32272","DOI":"10.1371\/journal.pone.0032272","volume":"7","author":"S Noda","year":"2012","unstructured":"Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, et al. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One. 2012;7(2):e32272.","journal-title":"PLoS One"},{"issue":"3","key":"3130_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/rheumatology\/keac411","volume":"62","author":"JE Mouawad","year":"2023","unstructured":"Mouawad JE, Sharma S, Renaud L, Pilewski JM, Nadig SN, Feghali-Bostwick C. Reduced Cathepsin L expression and secretion into the extracellular milieu contribute to lung fibrosis in systemic sclerosis. Rheumatology (Oxford). 2023;62(3):1306\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3130_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","volume":"73","author":"J Wei","year":"2014","unstructured":"Wei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, et al. A synthetic PPAR-\u03b3 agonist triterpenoid ameliorates experimental fibrosis: PPAR-\u03b3-independent suppression of fibrotic responses. Ann Rheum Dis. 2014;73(2):446\u201354.","journal-title":"Ann Rheum Dis"},{"key":"3130_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3389\/fphys.2020.00742","volume":"11","author":"M Su","year":"2020","unstructured":"Su M, Fan S, Ling Z, Fan X, Xia L, Liu Y, et al. Restoring the platelet miR-223 by calpain inhibition alleviates the neointimal hyperplasia in diabetes. Front Physiol. 2020;11:742.","journal-title":"Front Physiol"},{"issue":"10","key":"3130_CR35","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1111\/jcmm.17295","volume":"26","author":"H Deng","year":"2022","unstructured":"Deng H, Tian X, Sun H, Liu H, Lu M, Wang H. Calpain-1 mediates vascular remodelling and fibrosis via HIF-1\u03b1 in hypoxia-induced pulmonary hypertension. J Cell Mol Med. 2022;26(10):2819\u201330.","journal-title":"J Cell Mol Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03130-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:00:48Z","timestamp":1700240448000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03130-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3130"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03130-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2881053\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Committee on Animal Experimentation at the University of Fukui (number R03074).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}